Open an account

Tarsus Pharmaceuticals

TARS · NASDAQ

$71.03+$1.53 (+2.20%)TodayMarket closed ·
Prev close $69.50

About TARS

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 370 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Employees
370
Headquarters
Irvine, California
Listed
Oct 16, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
tarsusrx.com

TARS key statistics

Market cap
3.50B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
983.98K
Volume
898.99K
Open price
$69.54
High today
$72.46
Low today
$67.93
52 Week high
$91.53
52 Week low
$53.89

Tarsus Pharmaceuticals (TARS) at a glance

As of Oct 20, 2026, Tarsus Pharmaceuticals (TARS) shares are priced at $71.03, giving the company a market cap of 3.50B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $67.93 and $72.46. The current price is 4.6% above the day's low and 2.0% below its high.

Volume so far is 898.99K shares, in line with the average of 983.98K shares a day.

Over the past year Tarsus Pharmaceuticals has ranged from $53.89 to $91.53, and now sits 46% of the way up that range.

Tarsus Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.49 per share against an estimate of -$0.1999.

The average analyst price target is $101.55, 43.0% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $101.55
Low
$84.84
Now
$71.03
High
$121.80

TARS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 29.4% on average.

  1. Q3 FY24: reported -$0.61 per share against an estimate of -$0.992
  2. Q4 FY24: reported -$0.60 per share against an estimate of -$0.7574
  3. Q1 FY25: reported -$0.64 per share against an estimate of -$0.7452
  4. Q2 FY25: reported -$0.48 per share against an estimate of -$0.4076
  5. Q3 FY25: reported -$0.30 per share against an estimate of -$0.3574
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.097
  7. Q1 FY26: reported -$0.16 per share against an estimate of -$0.3778
  8. Q2 FY26: reported -$0.49 per share against an estimate of -$0.1999

TARS news

  • Vandana Singh

    Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

  • Evette Mitkov

    Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

  • Press releaseBusiness Wire

    Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

  • Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

  • Press releasePRNewswire

    Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

  • An Overview of Tarsus Pharmaceuticals's Earnings

  • Press releaseBusiness Wire

    Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

  • Press releaseBusiness Wire

    Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Similar companies

Companies in the same industry as Tarsus Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.